Efficacy and Safety of Streptokinase and Tenecteplase in Patients with ST Elevation Myocardial Infarction

Objective: To investigate the efficacy and safety of Streptokinase (STK) and Tenecteplase (TNK) in ST elevation myocardial infarction patients. Study Design: Randomized control trial. Place and duration: Study was conducted at Ch Pervaiz Ellahi institute of cardiology hospital Multan from May 2022 to April 2023. Methodology: Patients of ST elevation myocardial infarction presented within six hours of onset of symptoms were included in the study. Patients were divided into two equal groups (STK and TNK). Patients in STK group were thrombolysed with streptokinase and in TNK group were treated with Tenecteplase. SPSS version 23 was used for data analysis. Results: ST-resolution Pre-PCI at 90 minutes in STK and TNK groups was observed as 68% and 80%, respectively. While post-PCI ST-resolution was found in 80% and 88% patients of STK and TNK groups, respectively. Major bleeding events were found in 8% patients of STK Group and in 4% patients of TNK Group. The differences were statistically insignificant, and no association was found. Conclusion: Both drugs Streptokinase and Tenecteplase are equally effective when given in correct timeline in patients of ST segment myocardial infarction. Efficacy and safety of TNK is also like STK when administered in equal time frame.